According to Dr. Laudenslager and Hall, taking GLP1-s can indeed decrease bone density for some people. But that’s likely due ...

Fatty liver disease has become one of the most common liver conditions globally, closely tied to rising rates of obesity and metabolic disorders. Often described as a silent disease, it can progress ...

Why childhood obesity is becoming a cause for concern in a country that now ranks second globally for kids who are overweight ...

A new UNC School of Medicine study of incretin-based medications, including newer medications such as semaglutide and ...

More and more patients are developing type 2 diabetes while still young. The diagnosis may lead to a life of disease.

One quick intervention won't drastically lower heart disease, obesity and diabetes rates. It will take a long game and a ...

The trial of 2,700 patients with increased cardiovascular risk showed that Foundayo lowered ‌the risk of heart attack, stroke ...

A new study on obesity reveals that it affects men and women differently. Here are the hidden health risks and differences in ...

Eli Lilly and Company India President and General Manager Winselow Tucker on Mounjaro’s rapid rise and the country’s unmet ...

A DPV registry study of 7298 young adults with pediatric-onset T1D reveals significant undertreatment of hypertension and dyslipidemia.

A study of over 620,000 people found that weight gain in your 20s carries disproportionately high and lasting risks of ...

An Excel-based actuarial model (1 million lives; 49% eligible; 10% treated) estimated semaglutide coverage could be ...